Relief Therapeutics
About Relief Therapeutics
Relief Therapeutics aims to become a key player in the biotechnology and pharmaceutical industry.We will provide patients with therapeutic relief from diseases for which high needs persist.
We strongly believe that only by effectively treating patients will our investors realize significant return on investment.
Our areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets.
Our experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential.
Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decisive results.
YEAR FOUNDED:
1956
LEADERSHIP:
CEO: Raffaele Petrone
CFO: Tim Snyder
COO: Gael Hedou
CSO: Yves Sagot
Chief Business Officer: Michel Dreano
Chief Development Officer: Dorian Bevec
221 articles about Relief Therapeutics
-
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
1/6/2022
RELIEF THERAPEUTICS reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc. has announced that it has submitted an application to the FDA seeking EUA for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial.
-
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
-
Relief Therapeutics to Participate in Virtual Investor Conferences in January 2022
1/5/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced participation in the following virtual investor conferences in January.
-
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
1/4/2022
RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc. has announced that it has filed a provisional composition of matter patent application with the U.S. Patent and Trademark Office entitled, "Stable, Buffer-free Compositions of Vasoactive Intestinal Peptide."
-
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
1/3/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, gives notice of the Extraordinary General Meeting of shareholders to be held on Friday, January 28, 2022.
-
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
12/30/2021
RELIEF THERAPEUTICS Holding SA reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced it has filed for a new Breakthrough Therapy Designation request with the U.S. FDA focused on patients with Critical COVID-19 and respiratory failure who are at immediate risk of death despite treatment with Remdesivir and other approved therapies.
-
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
12/28/2021
RELIEF THERAPEUTICS Holding SA reported that the Swiss Patent Office IPI has announced that it expects to conclude the patent application procedure by January 24, 2022 and to issue the patent entitled, "Vasoactive Intestinal Peptide for the Use in the Treatment of Drug-induced Pneumonitis," as applied for by Relief's subsidiary, AdVita Lifescience GmbH, in 2020.
-
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
12/16/2021
RELIEF THERAPEUTICS Holding SA, announced that it has filed a Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission to register Relief as a reporting company under the Securities Exchange Act of 1934.
-
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
12/15/2021
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced a new safety update on aviptadil, which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the U.S. National Institutes of Health.
-
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
12/10/2021
RELIEF THERAPEUTICS Holding SA reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced it has agreed with Hungarian Health Officials on a regulatory path for emergency use of aviptadil in the Central European region, beginning with a compassionate care program, expected to begin by the end of 2021.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Relief Therapeutics Announces Executive Changes
11/30/2021
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced a series of executive changes.
-
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
11/29/2021
RELIEF THERAPEUTICS Holding SA reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced it completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with aviptadil in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir.
-
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
11/24/2021
RELIEF THERAPEUTICS Holding SA, announced that it has signed a collaboration agreement with InveniAI LLC, a U.S. based company that has pioneered the application of artificial intelligence and machine learning across biopharma and other industries, in order to identify promising drug candidates to treat rare and specialty diseases.
-
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
11/24/2021
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has issued a CEO Update announcing that the U.S. Food and Drug Administration has denied Breakthrough Therapy Designation for aviptadil.
-
Relief Therapeutics Launches Level 1 ADR Program in the United States
11/18/2021
RELIEF THERAPEUTICS Holding SA, announced that its Form F-6 registration statement has become effective, and that Relief has launched its Level 1 American Depositary Receipt program in the United States.
-
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
11/12/2021
RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing receipt of the U.S. Food and Drug Administration's response to NRx's October 8, 2021 submission of updated manufacturing information for aviptadil.
-
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
11/11/2021
RELIEF THERAPEUTICS Holding SA provided a corporate update detailing, among other matters, its ongoing clinical development and regulatory activities, as well as its plans to accelerate the maturation of its pipeline.
-
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
11/9/2021
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointment, effective December 1, 2021, of Anthony M. Kim as Senior Vice President and Head of U.S. Commercial Operations.
-
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
11/5/2021
RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing that it was declined Emergency Use Authorization by the U.S. Food and Drug Administration for the use of IV aviptadil for the treatment of acute respiratory failure due to critical COVID-19.